CY1110327T1 - DTPa ΕΜΒΟΛΙΑ ΒΛΕΝΝΟΓΟΝΟΥ - Google Patents

DTPa ΕΜΒΟΛΙΑ ΒΛΕΝΝΟΓΟΝΟΥ

Info

Publication number
CY1110327T1
CY1110327T1 CY20091100868T CY091100868T CY1110327T1 CY 1110327 T1 CY1110327 T1 CY 1110327T1 CY 20091100868 T CY20091100868 T CY 20091100868T CY 091100868 T CY091100868 T CY 091100868T CY 1110327 T1 CY1110327 T1 CY 1110327T1
Authority
CY
Cyprus
Prior art keywords
antigen
dtpa
pertussis
vaccines
mucosal
Prior art date
Application number
CY20091100868T
Other languages
English (en)
Inventor
Rino Rappuoli
Mariagrazia Pizza
Original Assignee
Novartis Vaccines And Diagnostics S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines And Diagnostics S.R.L. filed Critical Novartis Vaccines And Diagnostics S.R.L.
Publication of CY1110327T1 publication Critical patent/CY1110327T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/832—Drug, bio-affecting and body treating compositions involving bacterial toxin that has modified amino acid sequence
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Βλεννογόνοι DTPa εμβόλια, ειδικά ενδορηνικά εμβόλια, τα οποία περιλαμβάνουν (α) ένα αντιγόνο διφθερίτιδας, ένα αντιγόνο τετάνου και ένα ακυτταρικό αντιγόνο κοκκύτη, και (β) ένα αποτοξικοποιημένο μετάλλαγμα τοξίνης χολέρας (CT) ή θερμοευαίσθητης τοξίνης E.coli (LT). Το συστατικό (β) δρα σαν ένα βλεννογόνο ανοσοενισχυτικό. Το ακυτταρικό αντιγόνο κοκκύτη περιλαμβάνει ολοτοξίνη κοκκύτη (ΡΤ) και νηματοειδή αιμοσυγκολλητίνη (FHA) και, προαιρετικά, περτακτίνη. Το επιδιδόμενο δια του βλεννογόνου DTPa σκεύασμα είναι ικανό να παράγει ένα επίπεδο προστασίας έναντι της μόλυνσης από Β.pertussis ισοδύναμο με αυτό που παρατηρείται σε παρεντερική χορήγηση με ανοσοενισχυτικό στύψη.
CY20091100868T 1999-09-29 2009-08-12 DTPa ΕΜΒΟΛΙΑ ΒΛΕΝΝΟΓΟΝΟΥ CY1110327T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9923060.9A GB9923060D0 (en) 1999-09-29 1999-09-29 Vaccine
EP00962770A EP1223975B1 (en) 1999-09-29 2000-09-28 MUCOSAL DTPa VACCINES

Publications (1)

Publication Number Publication Date
CY1110327T1 true CY1110327T1 (el) 2015-01-14

Family

ID=10861826

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100868T CY1110327T1 (el) 1999-09-29 2009-08-12 DTPa ΕΜΒΟΛΙΑ ΒΛΕΝΝΟΓΟΝΟΥ

Country Status (12)

Country Link
US (1) US7279169B1 (el)
EP (1) EP1223975B1 (el)
JP (2) JP5025867B2 (el)
AT (1) ATE431744T1 (el)
CA (1) CA2386023C (el)
CY (1) CY1110327T1 (el)
DE (1) DE60042243D1 (el)
DK (1) DK1223975T3 (el)
ES (1) ES2323936T3 (el)
GB (1) GB9923060D0 (el)
PT (1) PT1223975E (el)
WO (1) WO2001022993A2 (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US20030021766A1 (en) 2001-01-12 2003-01-30 Michael Vajdy Nucleic acid mucosal immunization
BR0310042A (pt) * 2002-05-14 2005-04-05 Chiron Srl Vacinas de combinação mucosal para meningite bacteriana
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
CN105056229A (zh) 2009-01-05 2015-11-18 埃皮托吉尼西斯股份有限公司 佐剂组合物及使用方法
TW201103980A (en) * 2009-07-08 2011-02-01 Abbott Biologicals Bv Viral vaccine and use thereof
CA2839507A1 (en) 2011-06-24 2012-12-27 Epitogenesis Inc. Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators
WO2013141823A1 (en) * 2011-12-21 2013-09-26 Bionet-Asia, Co. Ltd Modified bordetella pertussis strains

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
IT1248735B (it) 1990-06-21 1995-01-26 Sclavo Spa Vaccini acellulari contro la pertosse
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
GB9513371D0 (en) 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
GB9209118D0 (en) 1992-04-28 1992-06-10 Sb 120 Amsterdam Bv Vaccine compositions
UA40596C2 (uk) 1992-05-23 2001-08-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини та спосіб її одержання
DE69434079T2 (de) * 1993-03-05 2005-02-24 Wyeth Holdings Corp. Plasmid zur Herstellung von CRM-Protein und Diphtherie-Toxin
JP3752264B2 (ja) * 1995-02-24 2006-03-08 財団法人化学及血清療法研究所 混合ワクチン
GB9622133D0 (en) 1996-10-24 1996-12-18 Niotech Limited Inverter circuits
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US7115730B1 (en) * 1999-04-27 2006-10-03 Chiron Srl Immunogenic detoxified mutant E. coli LT-A-toxin

Also Published As

Publication number Publication date
GB9923060D0 (en) 1999-12-01
PT1223975E (pt) 2009-08-26
WO2001022993A2 (en) 2001-04-05
DE60042243D1 (de) 2009-07-02
ATE431744T1 (de) 2009-06-15
JP2012067137A (ja) 2012-04-05
EP1223975A2 (en) 2002-07-24
JP5025867B2 (ja) 2012-09-12
CA2386023A1 (en) 2001-04-05
CA2386023C (en) 2011-04-26
JP2003510292A (ja) 2003-03-18
ES2323936T3 (es) 2009-07-28
DK1223975T3 (da) 2009-08-31
EP1223975B1 (en) 2009-05-20
US7279169B1 (en) 2007-10-09
WO2001022993A3 (en) 2001-10-25

Similar Documents

Publication Publication Date Title
CY1110327T1 (el) DTPa ΕΜΒΟΛΙΑ ΒΛΕΝΝΟΓΟΝΟΥ
MXPA03011135A (es) Formas mutantes de holotoxina de colera como adyuvante.
IL159210A0 (en) Mutant forms of cholera holotoxin as an adjuvant
FR11C0001I2 (fr) Vaccins combines contre neisseria meningitidis
WO2000057917A3 (en) Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
ATE186218T1 (de) Impfstoffzusammensetzungen fuer mukosale abgabe
ATE429928T1 (de) Proteinartige adjuvantien
DK1404363T3 (da) Adjuvanssammensætning til mucosalt og injektionsfremførte vacciner
CA2271008A1 (en) Acellular pertussis vaccine with diphtheria- and tetanus-toxoids
LU91155I2 (fr) Combinaison d'anatoxine diphtérique, d'anatoxine tétanique, d'anatoxine coquelucheuse, d'hémagglutininine filamenteuse, de pertactine, d'agglutinogènes fimbriaux coquelucheux 2 et 3 et de virus poliomyélitique inactivé type 1, type 2 et type 3.
WO2001097841A3 (en) Qs-21 and il-12 as an adjuvant combination
DK1024824T3 (da) Dispergerende vaccinesammensætning i fast form til oral indgivelse
EP1467771A4 (en) MYCOBACTERIAL VACCINE
WO2001070265A3 (en) Lipopeptide adjuvants
JP2003510292A5 (el)
AU7960101A (en) Parenteral vaccine formulations and uses thereof
GB9611501D0 (en) Vaccine compositions